COVID-19 booster shots could rake in billions for some vaccine makers
|globalnews.ca 25 Sep 2021 at 15:12|
Larger font Increase article font size
Billions more in profits are at stake for some vaccine makers as the U.S. moves toward dispensing COVID-19 booster shots to shore up Americans’ protection against the virus.
How much the manufacturers stand to gain depends on how big the rollout proves to be.
Exactly who should get a booster was a contentious decision as advisers to the Centers for Disease Control and Prevention spent two days this week poring over the evidence. CDC director Dr. RochelleWalensky endorsed most of their choices: People 65 and older, nursing home residents and those ages 50 to 64 who have chronic health problems such as diabetes should be offered one once they’re six months past their last Pfizer dose. Those 18 and older with health problems can decide for themselves if they want a booster.
Still, the crisis is constantly evolving, and some top U.S. health officials expect boosters will be more broadly authorized in the coming weeks or months. And that, plus continued growth in initial vaccinations, could mean a huge gain in sales and profits for Pfizer and Moderna in particular.